Year All202420232022202120202019 Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances Aug 16, 2024 Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models Aug 12, 2024 Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles Jul 19, 2024 Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management Jun 20, 2024 Altamira Therapeutics Provides Business Update May 28, 2024 Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal May 23, 2024 Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation May 01, 2024 Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal Apr 24, 2024 Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results Apr 10, 2024 Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 Apr 04, 2024
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances Aug 16, 2024
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models Aug 12, 2024
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles Jul 19, 2024
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management Jun 20, 2024
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal May 23, 2024
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation May 01, 2024
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal Apr 24, 2024
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results Apr 10, 2024
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 Apr 04, 2024
